disodium;hydrogen phosphate

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 碱金属含氧阴离子化合物
• 英文名称: disodium;hydrogen phosphate
• 化学式: HNa2O4P
• 分子量: 141.959
• InChiKey: BNIILDVGGAEEIG-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -8.18
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.4
• 氢给体数：
  1
• 氢受体数：
  4

ADMET

毒理性

• 吸入症状

咳嗽。喉咙痛。

Cough. Sore throat.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

毒理性

• 皮肤症状

红斑。疼痛。

Redness. Pain.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

毒理性

• 眼睛症状

红斑。疼痛。

Redness. Pain.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

毒理性

• 摄入症状

腹痛。腹泻。

Abdominal pain. Diarrhoea.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

毒理性

• 相互作用

除了D-甲状腺素，测试的降胆固醇药物并没有阻止大鼠在致血栓饮食及大剂量磷酸氢二钠治疗下形成心脏病变。

Except for D-thyroxine, the hypocholesterolemic agents tested did not prevent the formation of cardiac lesions in rats on a thrombogenic diet, being treated with large doses of disodium phosphate.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

• 吸收

口服给药的液体磷酸钠吸收的最大时间（Tmax）是1-3小时。

Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h.

来源:DrugBank

吸收、分配和排泄

磷酸盐（包括二碱性和单碱性磷酸钠）被缓慢且不完全吸收。/二碱性和单碱性磷酸钠/

... Phosphates (dibasic and monobasic sodium phosphate) are slowly and incompletely absorbed. /Dibasic and Monobasic Sodium phosphate/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

某些物种的小肠中可能会发生净磷吸收，但在马中，这主要是大肠的功能。/磷/

Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses. /Phosphorus/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

消除：肾脏（90%）和粪便（10%）。/磷酸盐/

Elimination: Renal (90%) and fecal (10%). /Phosphates/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

摄入的磷酸盐从胃肠道吸收。然而，大量的钙或铝的存在可能导致不溶性磷酸盐的形成，从而减少净吸收。维生素D可以刺激磷酸盐的吸收。/磷酸盐/

Ingested phosphates are absorbed from the gastrointestinal tract. However, the presence of large amounts of calcium or aluminum may lead to formation of insoluble phosphate and reduce the net absorption. Vitamin D stimulates phosphate absorption. /Phosphates/

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  disodium;hydrogen phosphate 生成
  参考文献：
  名称：

  MATSUKI, TAKEHTO;TAKEHSITA, TAKASI;KAMADA, XIDEHO;TANAKA, XIDEHMITSU

  摘要：

  DOI：
• 作为产物：
  描述：

  磷酸 生成 disodium;hydrogen phosphate
  参考文献：
  名称：

  AGAFONOV, A. A.;SHAPIRO, L. D.;KUSHERBEKOVA, G. T., TEZ. DOKL. BCEC. SEMIN. ZHOSFAT. MATER. ZH. 2/AN CCCP. NAUCH. COB. PO NEO+

  摘要：

  DOI：
• 作为试剂：
  描述：

  3-(3-Isoxazolyl)amino-7,8-dihydro-5H-pyrano[4,3-b]-pyridine-1-oxide 、 氯仿 、 硝酸 在 ice water 、 水 、 disodium;hydrogen phosphate 、 magnesium sulfate 、 resultant residue 、 甲醇 作用下， 反应 3.0h， 以to give 551 mg of the titled compound 6 as light yellow crystals的产率得到3-(3-Isoxazolyl)amino-4-nitro-7,8-dihydro-5H-pyrano-[4,3-b]pyridine-1-oxide
  参考文献：
  名称：

  Condensed imidazopyridine derivatives

  摘要：

  该化合物的分子式为： ##STR1## 其中R是可选取代的芳基基团或可选取代的芳香杂环基团；A环是一个5至9个成员的脂环基团，其中构成A环的一个或多个碳原子可被O或S取代，并且该A环可具有烷基取代基，或其药学上可接受的盐。

  公开号：

  US05378848A1

文献信息

• 4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
  申请人：——

  公开号：US20030125330A1

  公开（公告）日：2003-07-03

  Corticotropin releasing factor (CRF) antagonists of Formula (I): 1 and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

  Corticotropin releasing factor (CRF)拮抗剂的化学式(I):1及其在治疗焦虑、抑郁和其他精神、神经系统疾病方面的应用，以及治疗与心理病理障碍和压力相关的免疫、心血管或心脏相关疾病和结肠过敏反应。
• Novel process for the preparation of steroidal esters
  申请人：Plurichemie Anstalt

  公开号：US04655971A1

  公开（公告）日：1987-04-07

  A process for the preparation of corticosteriod esters of the formula ##STR1## in which ---- signifies that a double bond can be present; X is hydrogen, chlorine or fluorine; R.sub.1 is hydrogen, fluorine, chlorine or methyl, which may be either .alpha. or .beta.; R.sub.2 is halogen, oxo or hydroxyl; or R.sub.3 is hydrogen, .alpha.-methyl or .beta.-methyl; or R.sub.2 and X jointly form an epoxide group; R.sub.4 is an acyl group of the formula RCO, in which R is one of the following (i) an alkyl group containing 1 to 16 carbon atoms, whether straight-chained, branched or cyclic; (ii) an aralkyl group of 7 to 8 carbon atoms; (iii) a phenyl group; R.sub.5 is hydroxyl or R.sub.6 ; where R.sub.6 is hydrogen, one or two halogen atom substituents or OR.sub.7, where R.sub.7 is an acyl group of the formula R'CO in which R', which can be identical or different to R in the same molecule, is one of the following: (i) an alkyl group of 1 to 16 carbon atoms, whether straight-chained, branched or cyclic; (ii) an aralkyl group of 7 to 8 carbon atoms; or (iii) a phenyl group. which comprises esterifying a compound of the formula ##STR2## wherein X, R.sub.1, R.sub.3 and R.sub.5 are as defined above, and R.sub.8 is trihaloacetate, halogen or oxo, or jointly forms an epoxide group with X; at the 17-position only, or at the 17- and 21-positions when R.sub.5 in formula III is hydroxyl, the said esterification being carried out with the anhydride of the acid containing the group desired.

  一种制备糖皮质激素酯的方法，其中该酯的化学式为##STR1## 其中——表示可以存在双键；X为氢、氯或氟；R.sub.1为氢、氟、氯或甲基，可以是.alpha.或.beta.；R.sub.2为卤素、氧代或羟基；或者R.sub.3为氢、.alpha.-甲基或.beta.-甲基；或者R.sub.2和X共同形成环氧基团；R.sub.4为化学式RCO的酰基，其中R为以下之一：(i) 1至16个碳原子的烷基，无论是直链、支链还是环状；(ii) 7到8个碳原子的芳基烷基；(iii) 苯基；R.sub.5为羟基或R.sub.6，其中R.sub.6为氢、一个或两个卤素原子取代基或OR.sub.7，其中R.sub.7为化学式R'CO的酰基，其中R'可以与同一分子中的R相同或不同，为以下之一：(i) 1至16个碳原子的烷基，无论是直链、支链还是环状；(ii) 7到8个碳原子的芳基烷基；或(iii) 苯基。该方法包括酯化以下化合物的步骤##STR2## 其中X、R.sub.1、R.sub.3和R.sub.5如上定义，R.sub.8为三卤代乙酸酯、卤素或氧代，或与X共同形成环氧基团；仅在17位或在R.sub.5为羟基的情况下在17位和21位进行酯化反应，所述酯化反应是用所需羧酸的无水酸酐进行的。
• Cathepsin cysteine protease inhibitors
  申请人：Bayly I. Christopher

  公开号：US20050240023A1

  公开（公告）日：2005-10-27

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  本发明涉及一种新型化合物类别，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• Derivatives of perhydro-aza-heterocycles
  申请人：Ciba-Geigy Corporation

  公开号：US04160837A1

  公开（公告）日：1979-07-10

  The present invention provides new derivatives of perhydro-aza-heterocycles of the formula ##STR1## in which X is the oxo radical or hydrogen and the radical OR.sub.1, in which R.sub.1 is hydrogen or a substituted or unsubstituted aliphatic hydrocarbon radical, a substituted or unsubstituted araliphatic hydrocarbon radical or a substituted or unsubstituted aromatic hydrocarbon radical or an acyl radical, R.sub.2 is hydrogen or a substituted or unsubstituted aliphatic hydrocarbon radical, Y is oxygen or sulphur, n.sub.1 and n.sub.2 each are values of 1 to 3, n.sub.1 +n.sub.2 being at most four, and Ar is a substituted or unsubstituted aromatic hydrocarbon radical, and the acid addition salts, in particular the pharmaceutically acceptable acid addition salts thereof. These new substances possess valuable pharmacological properties, in particular antidepressant activity, and can be used for the treatment of mental depressions. Specific embodiments are trans- and cis-3-hydroxy-4-(3,4-dimethyl-phenoxy)-piperidine, trans- and cis-3-hydroxy-4-(2,3-dimethyl-phenoxy)-piperidine, their 1-methyl derivatives and the pharmaceutically acceptable salts of these substances.

  本发明提供了新的过氢化-氮杂杂环衍生物，其化学式为##STR1## 其中X为氧代基或氢，基OR.sub.1为氢或取代或未取代的脂肪烃基、取代或未取代的芳基脂肪烃基或取代或未取代的芳香烃基或酰基，基R.sub.2为氢或取代或未取代的脂肪烃基，Y为氧或硫，n.sub.1和n.sub.2各自为1至3的值，n.sub.1 +n.sub.2最多为4，Ar为取代或未取代的芳香烃基，以及酸加成盐，特别是其药学上可接受的酸加成盐。这些新物质具有有价值的药理学特性，特别是抗抑郁活性，可以用于治疗精神抑郁。具体实施例包括反式和顺式-3-羟基-4-(3,4-二甲基-苯氧基)-哌啶，反式和顺式-3-羟基-4-(2,3-二甲基-苯氧基)-哌啶，它们的1-甲基衍生物和这些物质的药学上可接受的盐。
• Methods and intermediates for preparing cis-4-oxoazetidine intermediates
  申请人：SmithKline Corporation

  公开号：US04166816A1

  公开（公告）日：1979-09-04

  The stereospecific cycloaddition of nitrogen containing acetic acid halides or anhydrides with Schiff bases having a carbalkoxy group substituted on the methine carbon atom offers new intermediates and methods for preparing synthetic cephalosporin congeners having antibacterial activity.

  含氮乙酸卤代物或酐与在甲基碳原子上具有碳酰氧基的Schiff碱的立体特异性环加成提供了新的中间体和制备具有抗菌活性的合成头孢菌素类似物的方法。

表征谱图